Trump Administration Directs Medicaid and CHIP to End Coverage of Gender-Affirming Hormones and Surgeries for Minors

The policy announcement follows a social media directive from President Trump to CMS Administrator Mehmet Oz and continues a pattern of federal restrictions that began in 2025. It explicitly preserves funding for mental health services while removing reimbursement for medical interventions. Twenty-seven states already prohibit these treatments for minors, and several large hospital systems have curtailed programs even in permissive jurisdictions.

Major medical organizations including the American Medical Association continue to endorse access to gender-affirming care, citing observational data on reduced dysphoria. In contrast, the American Society of Plastic Surgeons has stated that evidence for surgical benefit in minors remains insufficient. Systematic reviews published in the British Medical Journal and a 2024 Cass Review-style analysis in Sweden highlight the absence of high-quality randomized data and note high rates of psychiatric comorbidity that complicate attribution of outcomes.

Legal challenges are expected from groups such as GLBTQ Legal Advocates and Defenders. Prior administration actions on passports and youth sports have largely survived judicial review, but a lower court previously rejected the administration's safety declaration for these treatments. The rule does not alter state-level Medicaid flexibility or private insurance mandates in states without bans.

Implementation will require states to update billing systems and providers to counsel families on coverage loss. Long-term data collection on desistance, regret, and mental health trajectories after coverage withdrawal remains limited, underscoring the need for prospective cohort studies with standardized outcome measures.